Anlotinib in radioiodine-refractory differentiated thyroid carcinoma: A subanalysis based on ALTER01032 study for patients with poor baseline characteristics.
机构:[1]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[2]Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin Union Medical Center, Tianjin, China[3]Jiangsu Cancer Hospital (Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital), Nanjing, China[4]Hunan Cancer Hospital, Changsha, China[5]Jilin Cancer Hospital, Changchun, China[6]Sun Yat-sen University Cancer Center, Guangzhou, China[7]Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College/Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China浙江省肿瘤医院[8]Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[9]Harbin Medical University Cancer Hospital, Harbin, China[10]Tumor Hospital of China Medical University, Liaoning Tumor Hospital & Institute, Shenyang, China[11]Chongqing University Cancer Hospital, Chongqing Cancer Hospital, Chongqing, China[12]West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[13]Beijing Tongren Hospital, Capital Medical University, Beijing, China首都医科大学附属同仁医院[14]Fujian Cancer Hospital, Fuzhou, China[15]First Affiliated Hospital of Kunming Medical University, Kunming, China昆明医科大学附属第一医院[16]Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China
第一作者机构:[1]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[2]Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin Union Medical Center, Tianjin, China[3]Jiangsu Cancer Hospital (Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital), Nanjing, China[4]Hunan Cancer Hospital, Changsha, China[5]Jilin Cancer Hospital, Changchun, China[6]Sun Yat-sen University Cancer Center, Guangzhou, China[7]Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College/Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China[8]Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China[9]Harbin Medical University Cancer Hospital, Harbin, China[10]Tumor Hospital of China Medical University, Liaoning Tumor Hospital & Institute, Shenyang, China[11]Chongqing University Cancer Hospital, Chongqing Cancer Hospital, Chongqing, China[12]West China Hospital, Sichuan University, Chengdu, China[13]Beijing Tongren Hospital, Capital Medical University, Beijing, China[14]Fujian Cancer Hospital, Fuzhou, China[15]First Affiliated Hospital of Kunming Medical University, Kunming, China[16]Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China
推荐引用方式(GB/T 7714):
Chi Yihebali,Gao Ming,Zhang Yuan,et al.Anlotinib in radioiodine-refractory differentiated thyroid carcinoma: A subanalysis based on ALTER01032 study for patients with poor baseline characteristics.[J].JOURNAL OF CLINICAL ONCOLOGY.2021,39(15):doi:10.1200/JCO.2021.39.15_suppl.6022.
APA:
Chi, Yihebali,Gao, Ming,Zhang, Yuan,Shi, Feng,Cheng, Ying...&Tang, Pingzhang.(2021).Anlotinib in radioiodine-refractory differentiated thyroid carcinoma: A subanalysis based on ALTER01032 study for patients with poor baseline characteristics..JOURNAL OF CLINICAL ONCOLOGY,39,(15)
MLA:
Chi, Yihebali,et al."Anlotinib in radioiodine-refractory differentiated thyroid carcinoma: A subanalysis based on ALTER01032 study for patients with poor baseline characteristics.".JOURNAL OF CLINICAL ONCOLOGY 39..15(2021)